Overview

Safety, Tolerability and Immunogenicity of a Novel Inactivated Whole-cell Pneumococcal Vaccine Gamma PN-3.

Status:
Recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
This is a randomised placebo-controlled first-in-man dose-ranging study to determine safety and markers of efficacy.
Phase:
Phase 1
Details
Lead Sponsor:
GPN Vaccines
Treatments:
Heptavalent Pneumococcal Conjugate Vaccine